Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Slow release type linezolid preparation for eyes as well as preparation method and application thereof

A linezolid eye and linezolid technology are applied in the field of sustained-release linezolid ophthalmic preparations and their preparation, which can solve the problems of increasing the incidence of infectious endophthalmitis and the like, and achieve high intraocular bioavailability, The effect of strong targeting effect and good intraocular penetration

Inactive Publication Date: 2018-09-21
广州君博医药科技有限公司
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Subconjunctival and intravitreal injections can achieve effective drug concentrations in ocular tissues, but intraocular injections are, after all, a traumatic method of administration, and repeated injections will greatly increase the risk of infectious endophthalmitis. incidence rate

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Slow release type linezolid preparation for eyes as well as preparation method and application thereof
  • Slow release type linezolid preparation for eyes as well as preparation method and application thereof
  • Slow release type linezolid preparation for eyes as well as preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 8

[0032] (1) Embodiment 8 pharmacokinetic test

[0033] Healthy New Zealand rabbits (half male and half female) were used as experimental animals. A single dose of linezolid eye drops (at 20, 40, 60, 80, 100, 120, 150, 210, 270, 360, 480 minutes after administration, the aqueous humor 30 μl) and multiple times (7 days of continuous administration, 4 times a day, once every 6 hours. Take 30 μl of aqueous humor before the last administration on the 6th day, before the 1st and 2nd administration on the 7th day, At 20, 40, 60, 80, 100, 120, 150, 210, 270, 360, 480 min after the third administration, 30 μl of aqueous humor was extracted) After administration, the aqueous humor samples were determined by HPLC-MS.

[0034]After a single administration, the Cmax of linezolid in aqueous humor was 38.754±9.426g / ml; Tmax was 102.00±12.55min; T1 / 2 was 81.52±13.64min; AUC0-t was 5179.60±1881.16gminml-1, AUC0- was 5374.01±2056.85gminml-1; Ke is 0.01±0.001min-1. After repeated eye drops, the...

Embodiment 7

[0053] Pharmacokinetic test of linezolid eye drops prepared from sustained-release linezolid eye drops and DuraSite ophthalmic delivery system in Example 7

[0054] The left and right eyes of New Zealand rabbits were administered at the same time, and the dosage was 50 μL. At 20, 40, 60, 80, 100, 120, 150, 210, 270, 360, and 480 minutes after administration, 30 μl of aqueous humor was extracted for testing; aqueous humor samples were determined by LC-MS, and the results are shown in Table 4 below:

[0055] Table 4: The main pharmacokinetic parameters of the sustained-release linezolid eye drops and DuraSite linezolid eye drops in Example 7 administered to the eyes of New Zealand rabbits in a single dose

[0056]

[0057]

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
quality scoreaaaaaaaaaa
Login to View More

Abstract

The invention relates to a slow release type linezolid preparation for eyes as well as a preparation method and application thereof. The slow release type linezolid preparation is prepared from the following components: linezolid, polycarbophil, disodium edetate, an auxiliary material and water for injection, wherein the mass ratio of linezolid to polycarbophil to disodium edetate is 1 to (0.5 to2) to (0.05 to 0.2); the mass percent of linezolid is 0.1 percent to 1 percent. Dosage form of the preparation comprise eye drops, eye ointment and eye gel. The slow release type linezolid preparationhas a remarkable and long-lasting pharmaceutical effect, has good intraocular penetrability and relatively high intraocular bioavailability and has the advantages of strong penetration force, strongtargeting effect and small toxic and side effects; the slow release type linezolid preparation is suitable for treating and preventing outer eye and anterior segment diseases caused by non-infection inflammations and postoperative inflammations, and has good antibacterial and inflammation-diminishing effects, small irritation and high safety; raw materials are easy to obtain, a preparation processis simple and the cost is low; industrialized large-scale production can be realized and the economic benefit is remarkable.

Description

technical field [0001] The invention relates to an ophthalmic pharmaceutical preparation for treating bacterial infection, in particular to a slow-release linezolid ophthalmic preparation and its preparation method and application. Background technique [0002] Linezolid is a synthetic oxazolidinone antibiotic approved by the US FDA in 2000 for the treatment of infections caused by Gram-positive (G+) cocci, including suspected or confirmed hospital-acquired pneumonia (HAP) caused by MRSA, Community-acquired pneumonia (CAP), complicated skin or skin and soft tissue infection (SSTI), and vancomycin-resistant enterococci (VRE) infection. Linezolid is a brand-new class of oxazolone antibacterial drugs, which comprehensively covers drug-resistant strains of Gram-positive bacteria - Staphylococcus aureus / Enterococcus / Streptococcus, etc. It is an inhibitor of bacterial protein synthesis and acts on bacterial 50S ribosomes subunit and is closest to the site of action. Unlike o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/00A61K47/18A61K47/32A61K31/5377A61P31/04A61P27/02
CPCA61K9/0048A61K31/5377A61K47/183A61K47/32A61P27/02A61P31/04
Inventor 谭上彬王志军陈宇明黄俊杰崔明
Owner 广州君博医药科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com